https://www.selleckchem.com/pr....oducts/endoxifen-hcl
phorylation, cell-to-cell contact, cancer stem cell activation, and release of vascular endothelial growth factor. The BRAF mutation is an oncogenic driver associated with aggressive tumor behaviors and increased mortality among patients with papillary thyroid cancer (PTC). Although the BRAF inhibitor vemurafenib gave promising results in BRAF -mutant PTC, resistance development remains a major clinical challenge. This study aimed to explore the mechanisms underlying drug resistance in PTC. Two vemurafenib-resistant PTC cell lines
Like
Comment
Share
